ER+ tumors reclassified by BluePrint as Basal-type occur at a Read More
MammaPrint was the only test to predict significant 36% and Read More
Oral presentation at ASCO 2021 highlights long term data with Read More
Transcriptomic differences found between Luminal tumors in African American and Read More
Transcriptomic differences found between Luminal tumors in African American and Read More
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 12, 2021 Read More
Results support use of Agendia’s genomic tests to better tailor Read More
Agendia to Participate in the BTIG MedTech, Digital Health, Life Read More
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
